Alnylam Pharmaceuticals, Inc Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www....

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Poulton - CFO & Executive VP Pushkal P.

Shares of Alnylam Pharmaceuticals, Inc. surged after the company reported strong second quarter results. The revenue and EPS beats were driven by the very strong U.S. launch of Amvuttra for the treatment of ATTR amyloidosis cardiomyopathy. Sequential growth was driven by genuine demand, as 1,400 ATTR CM patients were on Amvuttra at the end of June.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. “Our results during the second quarter highlight Alnylam's unique ability to quickly deliver and enable commercial access to innovative medicin...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectation...

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.